Trial Profile
A Randomized Phase II Study Comparing Atezolizumab After Concurrent Chemo-radiotherapy With Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms ACHILES
- 04 Jan 2024 Planned End Date changed from 1 Dec 2026 to 1 Apr 2027.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2024.
- 02 May 2022 Status changed from recruiting to active, no longer recruiting.